346 POSTER Taxanes as adjuvant chemotherapy for early breast cancer: pooled-analysis of 15,000 patients enrolled in 8 randomized clinical trials

2005 ◽  
Vol 3 (2) ◽  
pp. 97
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Adjuvant Chemotherapy ◽  
Early Breast Cancer ◽  
Randomized Clinical Trials ◽  
Pooled Analysis

scholarly journals Adjuvant Dose-Dense Chemotherapy for Breast Cancer: Available Evidence and Recent Updates

Breast Care ◽  
2018 ◽  
Vol 13 (6) ◽  
pp. 447-452 ◽  
Author(s):  
Fernando Kude de Almeida ◽  
Daniela Dornelles Rosa
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Adjuvant Chemotherapy ◽  
Adverse Events ◽  
Early Breast Cancer ◽  
Hormone Receptor ◽  
Great Variability ◽  
Dose Dense

Adjuvant chemotherapy has greatly improved the prognosis of early breast cancer. Dose-dense chemotherapy seeks to increase efficacy by changing the interval between cycles of treatment without the need of increasing doses and toxicity. According to the Gompertzian model, the smaller tumors are and the more rapid they grow, the more benefit could be expected from dose-dense therapy. Some clinical trials showed reduced mortality when adjuvant chemotherapy is administered in shorter intervals, while others had discordant results. Interpreting results is difficult due to a great variability in doses and schemes used in different trials. Dose-dense chemotherapy does not seem to increase adverse events and appears to be the most efficacious in higher-risk individuals and in hormone receptor-negative tumors. This review intends to summarize the available evidence and recent research about this subject.

scholarly journals The Institute of Cancer Research, Clinical Trials and Statistics Unit (ICR-CTSU)

2006 ◽  
Vol 9 (S1) ◽  
pp. 305-329
Author(s):  
Keyword(s):  
Breast Cancer ◽  
Cancer Research ◽  
Clinical Trials ◽  
Adjuvant Chemotherapy ◽  
Randomized Trial ◽  
Early Breast Cancer ◽  
Hormone Replacement ◽  
List Type ◽  
Breast Radiotherapy ◽  
Whole Breast Radiotherapy

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by The Institute of Cancer Research, Clinical Trials and Statistics Unit (ICR-CTSU). Clinical trials include: The NCRI Adjuvant Breast Cancer (ABC) trial. ISRCTN31514446The UK randomized trial of hormone replacement therapy (HRT) in women with a history of early stage breast cancer. ISRCTN29941643NCRI Standardisation of Breast Radiotherapy (START) trial. ISRCTN59368779TACT: A randomized trial of standard anthracycline-based chemotherapy (fluorouracil, epirubicin and cyclophosphamide (FEC) or epirubicin and CMF (Epi-CMF)) versus FEC followed by sequential docetaxel in women with early breast cancer. ISRCTN 79718493SoFEA: Study of Faslodex with or without concomitant Arimidex versus Exemestane following progression on non-steroidal Aromatase inhibitors. ISRCTN: 44195747TACT2: Trial of accelerated adjuvant chemotherapy with Capecitabine in early breast cancer. ISRCTN68068041FAST trial: Prospective randomized clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control.IMPORT low trial.IMPORT high trial.Adjuvant chemotherapy in older women (ACTION).

Sign in / Sign up

Export Citation Format

Share Document